These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

872 related items for PubMed ID: 9619798

  • 21. Ritonavir and saquinavir combination therapy for the treatment of HIV infection.
    Cameron DW, Japour AJ, Xu Y, Hsu A, Mellors J, Farthing C, Cohen C, Poretz D, Markowitz M, Follansbee S, Angel JB, McMahon D, Ho D, Devanarayan V, Rode R, Salgo M, Kempf DJ, Granneman R, Leonard JM, Sun E.
    AIDS; 1999 Feb 04; 13(2):213-24. PubMed ID: 10202827
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Combination therapy containing ritonavir plus saquinavir has superior short-term antiretroviral efficacy: a randomized trial.
    Kirk O, Katzenstein TL, Gerstoft J, Mathiesen L, Nielsen H, Pedersen C, Lundgren JD.
    AIDS; 1999 Jan 14; 13(1):F9-16. PubMed ID: 10207539
    [Abstract] [Full Text] [Related]

  • 25. Increased risk of lipodystrophy when nucleoside analogue reverse transcriptase inhibitors are included with protease inhibitors in the treatment of HIV-1 infection.
    van der Valk M, Gisolf EH, Reiss P, Wit FW, Japour A, Weverling GJ, Danner SA, Prometheus study group.
    AIDS; 2001 May 04; 15(7):847-55. PubMed ID: 11399957
    [Abstract] [Full Text] [Related]

  • 26. Does race protect an oriental population from developing lipodystrophy in HIV-infected individuals on HAART?
    Chang KH, Kim JM, Song YG, Hong SK, Lee HC, Lim SK.
    J Infect; 2002 Jan 04; 44(1):33-8. PubMed ID: 11972416
    [Abstract] [Full Text] [Related]

  • 27. Virological treatment failure of protease inhibitor therapy in an unselected cohort of HIV-infected patients.
    Fätkenheuer G, Theisen A, Rockstroh J, Grabow T, Wicke C, Becker K, Wieland U, Pfister H, Reiser M, Hegener P, Franzen C, Schwenk A, Salzberger B.
    AIDS; 1997 Nov 15; 11(14):F113-6. PubMed ID: 9386799
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Impact of protease inhibitor substitution with efavirenz in HIV-infected children: results of the First Pediatric Switch Study.
    McComsey G, Bhumbra N, Ma JF, Rathore M, Alvarez A, First Pediatric Switch Study.
    Pediatrics; 2003 Mar 15; 111(3):e275-81. PubMed ID: 12612284
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Fasting hyperinsulinemia in human immunodeficiency virus-infected men: relationship to body composition, gonadal function, and protease inhibitor use.
    Hadigan C, Corcoran C, Stanley T, Piecuch S, Klibanski A, Grinspoon S.
    J Clin Endocrinol Metab; 2000 Jan 15; 85(1):35-41. PubMed ID: 10634360
    [Abstract] [Full Text] [Related]

  • 35. Lipodystrophy in HIV-infected pediatric patients receiving protease inhibitors.
    Temple ME, Koranyi KI, Nahata MC.
    Ann Pharmacother; 2003 Sep 15; 37(9):1214-8. PubMed ID: 12921501
    [Abstract] [Full Text] [Related]

  • 36. [Lipodystrophy and 'buffalo hump' during treatment with HIV protease inhibitors].
    Dieleman JP, Hillebrand-Haverkort ME, van der Ende ME, Sturkenboom MC, Lange JM, Stricker BH.
    Ned Tijdschr Geneeskd; 1998 Dec 26; 142(52):2856-60. PubMed ID: 10065260
    [Abstract] [Full Text] [Related]

  • 37. Syndrome of lipodystrophy, hyperlipidemia, insulin resistance, and diabetes in treated patients with human immunodeficiency virus infection.
    Graber AL.
    Endocr Pract; 2001 Dec 26; 7(6):430-7. PubMed ID: 11747278
    [Abstract] [Full Text] [Related]

  • 38. Diabetes, insulin resistance and dyslipidaemia in lipodystrophic HIV-infected patients on highly active antiretroviral therapy (HAART).
    Vigouroux C, Gharakhanian S, Salhi Y, Nguyen TH, Chevenne D, Capeau J, Rozenbaum W.
    Diabetes Metab; 1999 Sep 26; 25(3):225-32. PubMed ID: 10499191
    [Abstract] [Full Text] [Related]

  • 39. Safety and efficacy of ritonavir and saquinavir in combination with zidovudine and lamivudine.
    Michelet C, Bellissant E, Ruffault A, Arvieux C, Delfraissy JF, Raffi F, Bazin C, Renard I, Sébille V, Chauvin JP, Dohin E, Cartier F.
    Clin Pharmacol Ther; 1999 Jun 26; 65(6):661-71. PubMed ID: 10391672
    [Abstract] [Full Text] [Related]

  • 40. Efficacy, tolerance, and pharmacokinetics of the combination of stavudine, nevirapine, nelfinavir, and saquinavir as salvage regimen after ritonavir or indinavir failure.
    Casado JL, Dronda F, Hertogs K, Sabido R, Antela A, Martí-Belda P, Dehertogh P, Moreno S, NELSANE Study.
    AIDS Res Hum Retroviruses; 2001 Jan 20; 17(2):93-8. PubMed ID: 11177388
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 44.